Abstract
The current situation in the treatment of metastatic breast cancer is reviewed. Overall the concurrent use of endocrine treatment and chemotherapy does not improve the therapeutic results as compared to a treatment encompassing only one modality. However, results diverge widely in different subgroups. Data emerging from various randomized trials are beginning to define subgroups of patients, who should be treated differently. Such data are discussed and their importance for future trials in the field of advanced breast cancer reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 1129-1134 |
| Number of pages | 6 |
| Journal | Journal of Steroid Biochemistry |
| Volume | 23 |
| Issue number | 6 PART 2 |
| DOIs | |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology
Cite this
Hormono-chemotherapy in the treatment of advanced breast cancer. / Cavalli, F.; Goldhirsch, A.; Joss, R.; Brunner, K. W.
In: Journal of Steroid Biochemistry, Vol. 23, No. 6 PART 2, 1985, p. 1129-1134.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hormono-chemotherapy in the treatment of advanced breast cancer
AU - Cavalli, F.
AU - Goldhirsch, A.
AU - Joss, R.
AU - Brunner, K. W.
PY - 1985
Y1 - 1985
N2 - The current situation in the treatment of metastatic breast cancer is reviewed. Overall the concurrent use of endocrine treatment and chemotherapy does not improve the therapeutic results as compared to a treatment encompassing only one modality. However, results diverge widely in different subgroups. Data emerging from various randomized trials are beginning to define subgroups of patients, who should be treated differently. Such data are discussed and their importance for future trials in the field of advanced breast cancer reviewed.
AB - The current situation in the treatment of metastatic breast cancer is reviewed. Overall the concurrent use of endocrine treatment and chemotherapy does not improve the therapeutic results as compared to a treatment encompassing only one modality. However, results diverge widely in different subgroups. Data emerging from various randomized trials are beginning to define subgroups of patients, who should be treated differently. Such data are discussed and their importance for future trials in the field of advanced breast cancer reviewed.
UR - http://www.scopus.com/inward/record.url?scp=0022336421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022336421&partnerID=8YFLogxK
U2 - 10.1016/0022-4731(85)90031-7
DO - 10.1016/0022-4731(85)90031-7
M3 - Article
C2 - 3912617
AN - SCOPUS:0022336421
VL - 23
SP - 1129
EP - 1134
JO - Journal of Steroid Biochemistry
JF - Journal of Steroid Biochemistry
SN - 0022-4731
IS - 6 PART 2
ER -